儿童肺黏液表皮样癌的治疗进展
Progress in Treatment of Pulmonary Mucoepidermoid Carcinoma in Children
DOI: 10.12677/acm.2024.1441364, PDF,   
作者: 胡雨润：重庆医科大学附属儿童医院呼吸科，重庆；李渠北：国家儿童健康与疾病临床医学研究中心，重庆
关键词: 肺黏液表皮样癌；治疗；Pulmonary Mucoepidermoid Carcinoma； Treatment
摘要: 肺黏液表皮样癌(Pulmonary Mucoepidermoid Carcinoma, PMEC)是一种发起源于呼吸道黏膜下层导管上皮细胞的恶性肿瘤，因病例罕见，难以开展大规模的临床研究，目前对于PEMC的治疗还没有统一标准。完全切除所有肿瘤负荷是目前治疗的主要手段，但对于切除方式的选择还存在争议，并且对于不能手术切除的PMEC尚缺乏有效的治疗手段。本文就近年在儿童PMEC治疗方面的研究进展进行综述。
Abstract: Pulmonary mucoepidermoid carcinoma (PMEC) is a malignant tumor originating from the ductal epithelium of the respiratory tract submucosa. Due to the rare cases, large-scale clinical studies are difficult to be carried out. At present, there is no unified standard for the treatment of PEMC. At present, complete resection of all tumor burden is the main means of treatment, but the choice of resection method is still controversial, and there is still a lack of effective treatment for unresectable PMEC. This article reviews the recent research progress in the treatment of PMEC in children.
文章引用：胡雨润, 李渠北. 儿童肺黏液表皮样癌的治疗进展[J]. 临床医学进展, 2024, 14(4): 2851-2856. https://doi.org/10.12677/acm.2024.1441364

参考文献

[1] Travis, W.D., Brambilla, E., Burke, A.P., et al. (2015) Introduction to the 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. Journal of Thoracic Oncology, 10, 1240-1242. [Google Scholar] [CrossRef] 
[2] Gatta, G., Capocaccia, R., Botta, L., et al. (2017) Burden and Centralised Treatment in Europe of Rare Tumours: Results of RARECAREnet—A Population-Based Study. The Lancet Oncology, 18, 1022-1039. [Google Scholar] [CrossRef] 
[3] Qin, B., Jiao, X., Liu, K., et al. (2018) Clinical, Pathological and Treatment Factors Associated with the Survival of Patients with Primary Pulmonary Salivary Gland-Type Tumors. Lung Cancer, 126, 174-181. [Google Scholar] [CrossRef] [PubMed]
[4] Jaramillo, S., Rojas, Y., Slater, B.J., et al. (2016) Childhood and Adolescent Tracheobronchial Mucoepidermoid Carcinoma (MEC): A Case-Series and Review of the Literature. Pediatric Surgery International, 32, 417-424. [Google Scholar] [CrossRef] [PubMed]
[5] Roden, A.C., García, J.J., Wehrs, R.N., et al. (2014) Histopathologic, Immunophenotypic and Cytogenetic Features of Pulmonary Mucoepidermoid Carcinoma. Modern Pathology, 27, 1479-1488. [Google Scholar] [CrossRef] [PubMed]
[6] Song, Z., Liu, Z., Wang, J., et al. (2013) Primary Tracheobronchial Mucoepidermoid Carcinoma—A Retrospective Study of 32 Patients. World Journal of Surgical Oncology, 11, Article 62. [Google Scholar] [CrossRef] [PubMed]
[7] Techavichit, P., Hicks, M.J., López-Terrada, D.H., et al. (2016) Mucoepidermoid Carcinoma in Children: A Single institutional Experience. Pediatric Blood & Cancer, 63, 27-31. [Google Scholar] [CrossRef] [PubMed]
[8] 张谦, 曾骐, 陈诚豪, 等. 儿童气管黏液表皮样癌的外科治疗[J]. 中华小儿外科杂志. 2023, 44(5): 385-389.
[9] Abele, M., Bajčiová, V., Wright, F., et al. (2022) Primary Lung Carcinoma in Children and Adolescents: An Analysis of the European Cooperative Study Group on Paediatric Rare Tumours (EXPeRT). European Journal of Cancer, 175, 19-30. [Google Scholar] [CrossRef] [PubMed]
[10] Jieli, Z., Yunzhi, Z., Nan, Z., et al. (2021) Different Effects of Bronchoscopic Interventions on Children and Adults with Tracheobronchial Mucoepidermoid Carcinoma. Tumori Journal, 108, 134-140. [Google Scholar] [CrossRef] [PubMed]
[11] Wang, H., Zhang, J., Li, D., et al. (2015) Efficacy of Bronchoscopic Therapies for Bronchial Mucoepidermoid Carcinoma in Children: Results from Six Patients. Tumori Journal, 101, 52-56. [Google Scholar] [CrossRef] [PubMed]
[12] Yu, Y., Song, Z., Chen, Z., et al. (2011) Chinese Pediatric and Adolescent Primary Tracheobronchial Tumors: A Hospital-Based Study. Pediatric Surgery International, 27, 721-726. [Google Scholar] [CrossRef] [PubMed]
[13] Han, S.W., Kim, H.P., Jeon, Y.K., et al. (2008) Mucoepidermoid Carcinoma of Lung: Potential Target of EGFR-Directed Treatment. Lung Cancer, 61, 30-34. [Google Scholar] [CrossRef] [PubMed]
[14] Griffin, R. and Ramirez, R.A. (2017) Molecular Targets in Non-Small Cell Lung Cancer. Ochsner Journal, 17, 388-392.
[15] Wu, Y., Han, L., Sheng, Y., et al. (2020) Cetuximab Monotherapy for Relapsing High-Grade Mucoepidermoid Carcinoma: A Case Report and Review of the Literature. Oral Oncology, 107, Article 104824. [Google Scholar] [CrossRef] [PubMed]
[16] Milanovic, D., Jeremic, B., Kayser, G., et al. (2012) Relapsing High Grade Mucoepidermoid Carcinoma. Strahlentherapie und Onkologie, 188, 518-522. [Google Scholar] [CrossRef] [PubMed]
[17] Yamanaka, S., Suzuki, S., Ito, H., et al. (2023) Establishment of Mucoepidermoid Carcinoma Cell Lines from Surgical and Recurrence Biopsy Specimens. International Journal of Molecular Sciences, 24, Article 1722. [Google Scholar] [CrossRef] [PubMed]
[18] Shinomiya, H., Ito, Y., Kubo, M., et al. (2016) Expression of Amphiregulin in Mucoepidermoid Carcinoma of the Major Salivary Glands: A Molecular and Clinicopathological Study. Human Pathology, 57, 37-44. [Google Scholar] [CrossRef] [PubMed]
[19] Seto, E. and Yoshida, M. (2014) Erasers of Histone Acetylation: The Histone Deacetylase Enzymes. Cold Spring Harbor Perspectives in Biology, 6, a18713. [Google Scholar] [CrossRef] [PubMed]
[20] Ong, P.S., Wang, X.Q., Lin, H.S., et al. (2012) Synergistic Effects of Suberoylanilide Hydroxamic Acid Combined with Cisplatin Causing Cell Cycle Arrest Independent Apoptosis in Platinum-Resistant Ovarian Cancer Cells. International Journal of Oncology, 40, 1705-1713.
[21] Almeida, L.O., Abrahao, A.C., Rosselli-Murai, L.K., et al. (2014) NFκB Mediates Cisplatin Resistance through Histone Modifications in Head and Neck Squamous Cell Carcinoma (HNSCC). FEBS Open Bio, 4, 96-104. [Google Scholar] [CrossRef] [PubMed]
[22] Parag-Sharma, K., Tasoulas, J., Musicant, A.M., et al. (2021) Synergistic Efficacy of Combined EGFR and HDAC Inhibitors Overcomes Tolerance to EGFR Monotherapy in Salivary Mucoepidermoid Carcinoma. Oral Oncology, 115, Article 105166. [Google Scholar] [CrossRef] [PubMed]
[23] Ferrara, N. (2002) VEGF and the Quest for Tumour Angiogenesis Factors. Nature Reviews Cancer, 2, 795-803. [Google Scholar] [CrossRef] [PubMed]
[24] Kerbel, R.S. (2008) Tumor Angiogenesis. The New England Journal of Medicine, 358, 2039-2049. [Google Scholar] [CrossRef] 
[25] Mochizuki, D., Adams, A., Warner, K.A., et al. (2015) Anti-Tumor Effect of Inhibition of IL-6 Signaling in Mucoepidermoid Carcinoma. Oncotarget, 6, 22822-22835. [Google Scholar] [CrossRef] [PubMed]
[26] Ni, W., Chen, Z., Zhou, X., et al. (2021) Targeting Notch and EGFR Signaling in Human Mucoepidermoid Carcinoma. Signal Transduction and Targeted Therapy, 6, Article No. 27. [Google Scholar] [CrossRef] [PubMed]
[27] Keir, M.E., Butte, M.J., Freeman, G.J., et al. (2008) PD-1 and Its Ligands in Tolerance and Immunity. Annual Review of Immunology, 26, 677-704. [Google Scholar] [CrossRef] [PubMed]
[28] Aguilar, E.J., Ricciuti, B., Gainor, J.F., et al. (2019) Outcomes to First-Line Pembrolizumab in Patients with Non-Small-Cell Lung Cancer and Very High PD-L1 Expression. Annals of Oncology, 30, 1653-1659. [Google Scholar] [CrossRef] [PubMed]
[29] Incorvaia, L., Fanale, D., Badalamenti, G., et al. (2019) Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). Advances in Therapy, 36, 2600-2617. [Google Scholar] [CrossRef] [PubMed]
[30] Li, H., Shyam, S.S., Jatwani, K., et al. (2024) Tumor Characteristics and Treatment Responsiveness in Pembrolizumab-Treated Non-Small Cell Lung Carcinoma. Cancers, 16, Article 744. [Google Scholar] [CrossRef] [PubMed]
[31] Gyulai, M., Megyesfalvi, Z., Reiniger, L., et al. (2023) PD-1 and PD-L1 Expression in Rare Lung Tumors. Pathology and Oncology Research, 29, Article 1611164. [Google Scholar] [CrossRef] [PubMed]
[32] Zhang, Y., Zhang, Z., Ding, Y., et al. (2021) Phase I Clinical Trial of EGFR-Specific CAR-T Cells Generated by the PiggyBac Transposon System in Advanced Relapsed/Refractory Non-Small Cell Lung Cancer Patients. Journal of Cancer Research and Clinical Oncology, 147, 3725-3734. [Google Scholar] [CrossRef] [PubMed]
[33] Feng, K., Guo, Y., Dai, H., et al. (2016) Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of Patients with EGFR-Expressing Advanced Relapsed/Refractory Non-Small Cell Lung Cancer. Science China Life Sciences, 59, 468-479. [Google Scholar] [CrossRef] [PubMed]
[34] Liu, M., Wang, X., Li, W., et al. (2020) Targeting PD-L1 in Non-Small Cell Lung Cancer Using CAR T Cells. Oncogenesis, 9, Article No. 72. [Google Scholar] [CrossRef] [PubMed]

为你推荐